Quintanilha, Julia C. F. http://orcid.org/0000-0001-6908-4474
Geyer, Susan
Etheridge, Amy S.
Racioppi, Alessandro
Hammond, Kelli
Crona, Daniel J.
Peña, Carol E.
Jacobson, Sawyer B.
Marmorino, Federica
Rossini, Daniele
Cremolini, Chiara
Sanoff, Hanna K.
Abou-Alfa, Ghassan K.
Innocenti, Federico
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U10CA180821, U10CA180882, U24CA196171, UG1CA233373, UG1CA233290)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 4 March 2022
Revised: 12 April 2022
Accepted: 13 April 2022
First Online: 28 April 2022
Competing interests
: FI is an AbbVie employee and receives stocks from AbbVie; this work was conceived when FI was a faculty at the University of North Carolina at Chapel Hill, and this work does not represent a potential conflict of interest.
: The clinical studies were conducted in accordance with recognized ethical guidelines. The studies were performed in accordance with the Declaration of Helsinki and were approved by the local IRB. All participants provided written informed consent for sample collection and pharmacogenetic analysis.